Collectively, our findings suggest that although myeloid Pfkfb3 disruption decreases the pro-inflammatory macrophage profile in vitro, it does not affect atherosclerosis development in vivo, neither in advanced, nor early lesions. The gene discussed is PFKFB3; the disease is atherosclerosis.